[SFC바이오-관절 프로젝트] 논문 06. The Efficacy and Safety of Beef Tallow Extract Including Cis - 9 - cetylmyristoleate in Patients with Osteoarthritis - As an Adjuvant Pharmacological Treatment - > 자료실

본문 바로가기
자료실

자료실

[SFC바이오-관절 프로젝트] 논문 06. The Efficacy and Safety of Beef Tallow Extrac…

페이지 정보

작성자 최고관리자 댓글 0건 조회 363회 작성일 20-12-14 15:33

본문

1) 저널명 : J Food Science and Nutrition. 2005

2) 논문명 : The Efficacy and Safety of Beef Tallow Extract Including Cis - 9 - cetylmyristoleate in Patients with Osteoarthritis
                    - As an Adjuvant Pharmacological Treatment -

3) 요약
    In this double-blind, placebo-controlled trial, we assessed the efficacy and safety of beef tallow extract(BTE) including Cis-9-cetylmyristoleate in patients with arthritis.
    Between May and December 2003, we selected 80 patients (n=80) who showed/manifested arthritic symptoms and whose radiological findings were suggestive of arthritis,
    and randomly assigned them to placebo-controlled (n=40) and treatment group (n=40).
    The placebo (corn starch 350 mg) and BTE (208 mg) were orally administered to placebo-controlled and treatment group three times a day, respectively.
    We assessed the efficacy and safety based on the visual analogue scale (VAS) and modified knee society knee scores (MKSKS) at baseline and endpoint, respectively.
    To assess the safety, we monitored the adverse effects noted in liver, kidney, cardiovascular and gastrointestinal system for 3 weeks.
    Then, we performed not only a questionnaire study but also laboratory tests (e.g., liver function test, kidney function test, urinalysis, electrocardiography [EKG], complete blood cell counts [CBC] and chest X-ray).
    For statistical analysis, Student t-test and paired t-test were done using SPSS® Version11.0. Statistical significance was set at p<0.05.
    The scores between VAS and MKSKS showed statistical significance (p<0.05) with an improvement of 69.2% (27/39) and 3.8% (21/39) of treatment-group patients, respectively.
    Abnormal laboratory findings were noted in neither placebo-controlled nor treatment group.
    In conclusion, our results indicate that the administration of BTE was a safe and effective treatment regimen for patients with arthritis.
    In addition, the efficacy of BTE was more remarkable in alleviating the symptoms rather than improving the function.

첨부파일

댓글목록

등록된 댓글이 없습니다.


SFCBIO | 대표.김성규 | 서울특별시 강남구 언주로 725, 동관2층(논현동, 보전빌딩)
Tel.070-7830-6318 | Fax.02-6203-7171 | E-mail.siyou@sfcbio.com

Copyright © SFCBIO. All rights reserved. Hosting by Whalessoft.